Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
Department
Internal Medicine
Document Type
Article
Publication Title
Cancers
Abstract
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients. Second-generation SERDs were developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives.
First Page
619
DOI
10.3390/cancers16030619
Volume
16
Issue
3
Publication Date
1-31-2024
PubMed ID
38339371
Recommended Citation
Neupane, N., Bawek, S., Gurusinghe, S., Ghaffary, E. M., Mirmosayyeb, O., Thapa, S., Falkson, C., O'Regan, R., & Dhakal, A. (2024). Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers, 16 (3), 619. https://doi.org/10.3390/cancers16030619